Pharmacist Cardiovascular | Patient Safety | Treatment Guidelines Podcast 45 credit minutes

Beta-blockers have long been considered a foundational therapy following myocardial infarction, yet emerging data are challenging their routine use in all patients. This course discusses recent evidence on outcomes associated with beta-blocker therapy after MI, particularly in patients without reduced ejection fraction, and explores the ongoing debate over the benefits, risks, and duration of therapy. You will gain practical insight to support evidence-based decision-making and individualized pharmacotherapy recommendations in post-MI care. 

Available in Subscription

This course is included in the following subscription:

Pharmacist CE Subscription

Pharmacist CE Subscription

Renewed Annually
$99.00 / year

Learning Objectives

1. Summarize contemporary evidence regarding beta-blocker therapy after myocardial infarction.
2. Describe clinical considerations that may influence the decision to initiate, continue, or deprescribe beta-blocker therapy following myocardial infarction. 

Faculty

Rachel Maynard, PharmD

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Anna Crider, PharmD, BCCP

Disclosures:

Anna Crider has no relevant financial relationships with ineligible companies to disclose.

Taylor Merritt, PharmD

Disclosures:

Taylor Merritt has no relevant financial relationships with ineligible companies to disclose.

Course Details